In an elderly patient with HIV infection prescribed zidovudine (Retrovir), which laboratory test should be used to monitor for drug‑induced bone‑marrow suppression?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Complete Blood Count (CBC) is the Essential Test for Monitoring Zidovudine Side Effects

The complete blood count (CBC) is the diagnostic test required to assess zidovudine's primary side effect of bone marrow suppression, which manifests as anemia and neutropenia. 1

Why CBC is Critical for Zidovudine Monitoring

The FDA drug label for Retrovir (zidovudine) explicitly states that "frequent blood counts are strongly recommended to detect severe anemia or neutropenia" in patients treated with zidovudine 1. This is because:

Hematologic Toxicity Profile

  • Anemia develops early: Reduction in hemoglobin can occur as early as 2-4 weeks after starting therapy
  • Neutropenia follows: Typically occurs after 6-8 weeks of treatment
  • Pancytopenia is possible: All blood cell lines can be affected, though this is reversible after drug discontinuation in most cases 1

Monitoring Frequency Requirements

The FDA label specifies different monitoring intensities based on disease severity:

  • Advanced HIV disease with poor bone marrow reserve: Frequent blood counts are strongly recommended
  • Asymptomatic or early HIV disease: Periodic blood counts are recommended 1

Why the Other Tests Are Not Appropriate

  • Hemoglobin A1C: Used for diabetes screening, not relevant to zidovudine toxicity monitoring
  • Immunodeficiency panel: Assesses immune function (CD4 counts), not bone marrow suppression
  • Serum glucose: Monitors for metabolic complications, not hematologic toxicity

Clinical Context for Older Adults

This is particularly important in elderly patients because:

  • They may have pre-existing bone marrow compromise
  • The drug label warns against use in patients with granulocyte count <1,000 cells/mm³ or hemoglobin <9.5 g/dL 1
  • Dose interruption may be needed if anemia or neutropenia develops

Contemporary Practice Note

While current HIV guidelines 2 suggest that routine hematologic monitoring may not be necessary with modern first-line antiretroviral regimens (which rarely include zidovudine), zidovudine specifically requires CBC monitoring due to its well-established bone marrow toxicity 1, 3. A 2024 case report documented severe aplastic anemia occurring even after 11 years of zidovudine use, emphasizing the need for ongoing monitoring throughout therapy 3.

The answer is: Complete blood count.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.